SCHEMBL8259183

SCHEMBL8259183

CC(=O)c1ccc(C(F)(F)F)cc1N1CCC(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 1/20 0.50
TRPV1 Q8NER1 5/20 0.48
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
CYP2C9 P11712 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
FFAR4 Q5NUL3 1/20 0.43
NOTUM Q6P988 3/20 0.43
GAA P10253 2/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
NR4A1 P22736 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8255504 0.88 ALDH1A1 (0.51) SCN10ATRPV1MAPTKMT2AALDH1A1
SCHEMBL8259185 0.86 TRPV1 (0.46) SCN10ATRPV1MAPTKMT2AALDH1A1
SCHEMBL18412772 0.82 ALDH1A1 (0.63) ALDH1A1GAAKDM4EPOLB
SCHEMBL13176013 0.82 MAPT (0.49) MAPTKMT2AALDH1A1MEN1GAA
SCHEMBL8261932 0.80 ALDH1A1 (0.60) MAPTKMT2AALDH1A1MEN1CYP2C9
SCHEMBL13175832 0.80 CCR2 (0.41) SCN10ATRPV1KMT2AALDH1A1MEN1
SCHEMBL8260996 0.79 LIPG (0.46) SCN10ANOTUM
SCHEMBL8259624 0.79 MAPT (0.49) MAPTKMT2AALDH1A1NOTUMGAA
SCHEMBL13698912 0.78 GAA (0.45) MAPTALDH1A1CYP2C9GAAKDM4E
SCHEMBL8261938 0.77 ALDH1A1 (0.47) TRPV1MAPTKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228364-A1 Acylsulfonamides as inhibitors of steroid sulfatase Novartis AG (CH) 2010-09-15 EP disclosed
US-20090227620-A1 ANTI-INFLAMMATORY COMPOUNDS MEINGASSNER JOSEF GOTTFRIED 2009-09-10 US disclosed
US-20090227620-A1 ANTI-INFLAMMATORY COMPOUNDS MEINGASSNER JOSEF GOTTFRIED 2009-09-10 US disclosed
US-7482462-B2 Acylsulfonamides as inhibitors of steroid sulfatase NOVARTIS AG (CH) 2009-01-27 US disclosed
US-7482462-B2 Acylsulfonamides as inhibitors of steroid sulfatase NOVARTIS AG (CH) 2009-01-27 US disclosed
US-20080293758-A1 Combination of a Steroid Sulfatase Inhibitor and an Ascomycin NOVARTIS AG (CH) 2008-11-27 US disclosed
US-20080293758-A1 Combination of a Steroid Sulfatase Inhibitor and an Ascomycin NOVARTIS AG (CH) 2008-11-27 US disclosed
WO-2006097293-A2 COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN NOVARTIS AG (CH) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293758-A1 Combination of a Steroid Sulfatase Inhibitor and an Ascomycin STS, ARSA, CYP17A1 SCN10A 3426/4885TRPV1 4764/4885MAPT 3209/4885
US-20090227620-A1 ANTI-INFLAMMATORY COMPOUNDS STS, SERPINB1, MPO SCN10A 1997/4885TRPV1 1600/4885MAPT 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.